BATF2 (Vector pENTR223.1, Accession No. BC012330)

Length: 570 Sequence: atggattgtg cctcctgctc agctccaggg ctcctgggct gctgggacca ggctgagggg ctcctgggcc ctggcccaca gggacaacat ggctgccggg agcagctgga gctgttccag accccgggtt cctgttaccc agctcagccg ctctctccag gtccacagcc tcatgattct cccagcctcc tccagtgccc cctgccctca ctgtcccttg gccccgctgt ggttgctgaa cctcctgtcc agctgtcccc cagccctctc ctgtttgcct cgcacactgg ttccagcctg caggggtctt cctctaagct cagtgccctc cagcccagcc tcacggccca aactgcccct ccacagcccc tcgagctgga gcatcccacc agagggaagc tggggtcctc tcccgacaac ccttcctctg ccctggggct tgcacgtctg cagagcaggg agcacaaacc tgctctctca gcagccactt ggcaagggct ggttgtggat cccagccctc accctctcct ggcctttcct ctgctctcct ctgctcaagt Protein function: AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system. Following infection, participates in the differentiation of CD8(+) thymic conventional dendritic cells in the immune system. Acts via the formation of a heterodimer with JUN family proteins that recognizes and binds DNA sequence 5'-TGA[CG]TCA-3' and regulates expression of target genes. Selectively suppresses CCN1 transcription and hence blocks the downstream cell proliferation signals produced by CCN1 and inhibits CCN1-induced anchorage-independent growth and invasion in several cancer types, such as breast cancer, malignant glioma and metastatic melanoma. Possibly acts by interfering with AP-1 binding to CCN1 promoter. [The UniProt Consortium]